Compile Data Set for Download or QSAR
Report error Found 4790 Enz. Inhib. hit(s) with Target = 'Bile acid receptor'
TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM21674(Chenodeoxycholic Acid | CDCA | (4R)-4-[(1S,2S,5R,7...)
Affinity DataEC50: >1.00E+3nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM303496(US10138228, Example 1)
Affinity DataEC50:  550nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM303497(US10138228, Example 2)
Affinity DataEC50:  5.50E+3nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM303498(US10138228, Example 3)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM21674(Chenodeoxycholic Acid | CDCA | (4R)-4-[(1S,2S,5R,7...)
Affinity DataEC50: >1.00E+4nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM21675(6alpha-Ethyl-Chenodeoxycholic Acid | (4R)-4-[(1S,2...)
Affinity DataEC50:  550nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM304497(US10144729, Example 2a)
Affinity DataEC50:  5.50E+3nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM304498(US10144729, Example 2b)
Affinity DataEC50:  550nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM304715(US10144729, Example 2c)
Affinity DataEC50:  550nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM304716(US10144729, Example 2d)
Affinity DataEC50:  550nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM304717(US10144729, Example 1a)
Affinity DataEC50:  550nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM304718(US10144729, Example 1b)
Affinity DataEC50:  5.50E+3nMAssay Description:The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Repor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM21674(Chenodeoxycholic Acid | CDCA | (4R)-4-[(1S,2S,5R,7...)
Affinity DataEC50: >1.00E+4nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM306710(US10149835, Example 1)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM306711(US10149835, Example 2)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM306712(US10149835, Example 3)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM306713(US10149835, Example 4)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM306714(US10149835, Example 5)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM306715(US10149835, Example 6)
Affinity DataEC50: <100nMAssay Description:Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322134(US10183917, Example 1 | 8-((5-cyclopropyl-3-(2,6-d...)
Affinity DataEC50:  18nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322135(US10183917, Example 15)
Affinity DataEC50:  35nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322134(US10183917, Example 1 | 8-((5-cyclopropyl-3-(2,6-d...)
Affinity DataEC50:  4nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322137(US10183917, Example 17)
Affinity DataEC50:  23nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322138(US10183917, Example 3)
Affinity DataEC50:  37nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322139(US10183917, Example 19)
Affinity DataEC50:  6nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322140(US10183917, Example 4)
Affinity DataEC50:  46nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322141(US10183917, Example 27)
Affinity DataEC50:  12nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322142(US10183917, Example 5)
Affinity DataEC50:  6nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322143(US10183917, Example 29)
Affinity DataEC50:  11nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322144(US10183917, Example 6)
Affinity DataEC50:  55nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322145(US10183917, Example 30)
Affinity DataEC50:  27nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322146(US10183917, Example 7)
Affinity DataEC50:  15nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322147(US10183917, Example 31)
Affinity DataEC50:  56nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322148(US10183917, Example 9)
Affinity DataEC50:  38nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322149(US10183917, Example 32)
Affinity DataEC50:  54nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322150(US10183917, Example 11)
Affinity DataEC50:  56nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM322151(US10183917, Example 33)
Affinity DataEC50:  18nMAssay Description:Purchasing invitrogen PV4833 kits.First, the required amount of the compound was weighed and dissolved in 100% DMSO at the maximum concentration of 3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM21674(Chenodeoxycholic Acid | CDCA | (4R)-4-[(1S,2S,5R,7...)
Affinity DataEC50: >1.00E+4nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM21675(6alpha-Ethyl-Chenodeoxycholic Acid | (4R)-4-[(1S,2...)
Affinity DataEC50:  550nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350695(US10208081, Example 1)
Affinity DataEC50: <100nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350696(US10208081, Example 2)
Affinity DataEC50: <100nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350697(US10208081, Example 127 | US10208081, Example 77 |...)
Affinity DataEC50: <100nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350698(US10208081, Example 4)
Affinity DataEC50: <100nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350699(US10208081, Example 5)
Affinity DataEC50:  550nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350700(US10208081, Example 6)
Affinity DataEC50:  550nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350701(US10208081, Example 7)
Affinity DataEC50:  5.50E+3nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350702(US10208081, Example 10 | US10266560, Example 18)
Affinity DataEC50:  550nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350703(US10208081, Example 11)
Affinity DataEC50:  5.50E+3nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350704(US10208081, Example 12)
Affinity DataEC50: <100nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetBile acid receptor(Human)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM350705(US10208081, Example 13)
Affinity DataEC50: <100nMAssay Description:The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

Displayed 1 to 50 (of 4790 total ) | Next | Last >>
Jump to: